Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
069620.KS Stock Summary
Top 10 Correlated ETFs
069620.KS
In the News
069620.KS Financial details
Company Rating
Buy
Market Cap
1201.26B
Income
49.28B
Revenue
1332.28B
Book val./share
59673.48
Cash/share
13087.6
Dividend
600
Dividend %
0.58%
Employees
1.72K
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
24.26
Forward P/E
-
PEG
2.54
P/S
0.9
P/B
1.74
P/C
7.94
P/FCF
68.24
Quick Ratio
0.62
Current Ratio
1.08
Debt / Equity
0.6
LT Debt / Equity
0.21
-
-
EPS (TTM)
4.35K
EPS next Y
-
EPS next Q
-
EPS this Y
77.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
4.41%
Revenue Q/Q
8.62%
EPS Q/Q
55.93%
-
-
-
-
SMA20
1.04%
SMA50
13.06%
SMA100
-1.23%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
8%
ROC
0.1%
Gross Margin
51%
Oper. Margin
8%
Profit Margin
4%
Payout
2%
Shs Outstand
11.51M
Shs Float
5.38M
-
-
-
-
Target Price
-
52W Range
88300.0-173000.0
52W High
-39.94%
52W Low
+17.67%
RSI
46
Rel Volume
0.33
Avg Volume
37.18K
Volume
12.26K
Perf Week
-4.24%
Perf Month
-6.14%
Perf Quarter
0.39%
Perf Half Y
-0.57%
-
-
-
-
Beta
1.01762
-
-
Volatility
1902.52%, 2313.17%
Prev Close
-0.48%
Price
103900
Change
-0.1%
069620.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 99.93K | 107.87K | 98.98K | 104.78K | 120.06K | |
Net income per share | -1.47K | 2.13K | 2.26K | 2.24K | 3.96K | |
Operating cash flow per share | 4.6K | 5.58K | 9.47K | 3.63K | 11.09K | |
Free cash flow per share | -926.43 | 725.99 | 3.87K | -3.16K | 460.1 | |
Cash per share | 12.85K | 12.58K | 16.61K | 15.79K | 13.19K | |
Book value per share | 47.87K | 50.31K | 51.67K | 52.12K | 57.02K | |
Tangible book value per share | 44.4K | 45.65K | 48.44K | 43.37K | 44.57K | |
Share holders equity per share | 47.87K | 50.31K | 51.67K | 52.12K | 57.02K | |
Interest debt per share | 38.41K | 39.05K | 42.79K | 41.43K | 42.68K | |
Market cap | 1914.62B | 1419.24B | 1759.46B | 1628.58B | 1711.33B | |
Enterprise value | 2236.14B | 1780.07B | 2132.85B | 1998.37B | 2055.09B | |
P/E ratio | -126.36 | 64.49 | 72.86 | 66.04 | 40.51 | |
Price to sales ratio | 1.86 | 1.27 | 1.67 | 1.41 | 1.34 | |
POCF ratio | 40.31 | 24.64 | 17.42 | 40.72 | 14.48 | |
PFCF ratio | -200.23 | 189.4 | 42.62 | -46.8 | 348.84 | |
P/B Ratio | 3.87 | 2.73 | 3.19 | 2.84 | 2.81 | |
PTB ratio | 3.87 | 2.73 | 3.19 | 2.84 | 2.81 | |
EV to sales | 2.17 | 1.6 | 2.02 | 1.73 | 1.61 | |
Enterprise value over EBITDA | 27.06 | 21.01 | 35 | 29.18 | 21.23 | |
EV to operating cash flow | 47.08 | 30.9 | 21.12 | 49.97 | 17.38 | |
EV to free cash flow | -233.85 | 237.55 | 51.66 | -57.42 | 418.91 | |
Earnings yield | -0.01 | 0.02 | 0.01 | 0.02 | 0.02 | |
Free cash flow yield | 0 | 0.01 | 0.02 | -0.02 | 0 | |
Debt to equity | 0.78 | 0.76 | 0.81 | 0.78 | 0.73 | |
Debt to assets | 0.32 | 0.32 | 0.33 | 0.31 | 0.29 | |
Net debt to EBITDA | 3.89 | 4.26 | 6.13 | 5.4 | 3.55 | |
Current ratio | 1.4 | 2.01 | 1.62 | 1.14 | 1.16 | |
Interest coverage | 2.56 | 4.43 | 1.6 | 2.69 | 6.79 | |
Income quality | -3.08 | 2 | 4.18 | 1.32 | 3.02 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.41 | 0.28 | 0.26 | 0.26 | 0.19 | |
Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
Research and developement to revenue | 0.11 | 0.1 | 0.11 | 0.11 | 0.13 | |
Intangibles to total assets | 0.12 | 0.13 | 0.13 | 0.16 | 0.17 | |
Capex to operating cash flow | -1.2 | -0.87 | -0.59 | -1.87 | -0.96 | |
Capex to revenue | -0.06 | -0.05 | -0.06 | -0.06 | -0.09 | |
Capex to depreciation | -1.11 | -1.25 | -1.46 | -1.83 | -2.85 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 39.77K | 49.13K | 51.31K | 51.27K | 71.29K | |
ROIC | 0.69 | 0.06 | 0.03 | 0.04 | 0.05 | |
Return on tangible assets | -0.01 | 0.02 | 0.02 | 0.02 | 0.03 | |
Graham Net | -22.17K | -22.16K | -25.88K | -29.16K | -40.31K | |
Working capital | 148.27B | 264.18B | 201.6B | 64.23B | 76.14B | |
Tangible asset value | 458.24B | 471.23B | 516.51B | 477.24B | 475.22B | |
Net current asset value | -84.37B | -83.49B | -143.31B | -187.88B | -273.15B | |
Invested capital | 0.78 | 0.76 | 0.81 | 0.78 | 0.73 | |
Average receivables | 188.1B | 204.35B | 196.01B | 174.86B | 185.29B | |
Average payables | 60.85B | 69.48B | 77.74B | 74.82B | 77.13B | |
Average inventory | 188.03B | 183.32B | 175.79B | 174.51B | 191.89B | |
Days sales outstanding | 68 | 70.98 | 60.69 | 55.16 | 55.99 | |
Days payables outstanding | 36.57 | 44.08 | 47.26 | 42.52 | 47.48 | |
Days of inventory on hand | 111.02 | 102.07 | 104.36 | 105.05 | 118.83 | |
Receivables turnover | 5.37 | 5.14 | 6.01 | 6.62 | 6.52 | |
Payables turnover | 9.98 | 8.28 | 7.72 | 8.58 | 7.69 | |
Inventory turnover | 3.29 | 3.58 | 3.5 | 3.47 | 3.07 | |
ROE | -0.03 | 0.04 | 0.04 | 0.04 | 0.07 | |
Capex per share | -5.53K | -4.85K | -5.6K | -6.8K | -10.63K |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 29.1K | 29.98K | 29.61K | 28.85K | 30.43K | |
Net income per share | 1.58K | 1.85K | -1.03K | 1.38K | 2.15K | |
Operating cash flow per share | 1.41K | 2.76K | 4.3K | 2.26K | 2.85K | |
Free cash flow per share | 46.56 | 75.52 | 915.54 | -576.11 | 1.13K | |
Cash per share | 15.41K | 16.49K | 12.71K | 16K | 13.09K | |
Book value per share | 55.35K | 56.87K | 54.93K | 59.51K | 59.67K | |
Tangible book value per share | 44.23K | 45.28K | 42.93K | 46.28K | 47.04K | |
Share holders equity per share | 55.35K | 56.87K | 54.93K | 59.51K | 59.67K | |
Interest debt per share | 39.85K | 40.86K | 40.69K | 39.67K | 35.87K | |
Market cap | 1953.72B | 1748.93B | 1776.67B | 1175.53B | 1108.23B | |
Enterprise value | 2278.34B | 2064.87B | 2120.43B | 1476.53B | 1408.55B | |
P/E ratio | 27.96 | 21.33 | -39.06 | 19.07 | 11.2 | |
Price to sales ratio | 6.07 | 5.27 | 5.42 | 3.65 | 3.16 | |
POCF ratio | 125.48 | 57.23 | 37.33 | 46.58 | 33.85 | |
PFCF ratio | 3.79K | 2.09K | 175.31 | -182.6 | 85.34 | |
P/B Ratio | 3.19 | 2.78 | 2.92 | 1.77 | 1.61 | |
PTB ratio | 3.19 | 2.78 | 2.92 | 1.77 | 1.61 | |
EV to sales | 7.07 | 6.22 | 6.47 | 4.58 | 4.02 | |
Enterprise value over EBITDA | 57.29 | 51.63 | -177.41 | 9.29 | 7.69 | |
EV to operating cash flow | 146.33 | 67.57 | 44.55 | 58.5 | 43.02 | |
EV to free cash flow | 4.42K | 2.47K | 209.23 | -229.36 | 108.46 | |
Earnings yield | 0.01 | 0.01 | -0.01 | 0.01 | 0.02 | |
Free cash flow yield | 0 | 0 | 0.01 | -0.01 | 0.01 | |
Debt to equity | 0.73 | 0.71 | 0.73 | 0.66 | 0.6 | |
Debt to assets | 0.3 | 0.29 | 0.29 | 0.27 | 0.25 | |
Net debt to EBITDA | 8.16 | 7.9 | -28.76 | 1.89 | 1.64 | |
Current ratio | 1.38 | 1.34 | 1.16 | 1.19 | 1.08 | |
Interest coverage | -5.52 | 9.13 | 3.39 | 17.07 | 0 | |
Income quality | 0.96 | 1.44 | -4.19 | 1.83 | 1.14 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.38 | 0 | -0.07 | 0 | 0 | |
Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.42 | 0.41 | |
Research and developement to revenue | 0.12 | 0.12 | 0.14 | 0.14 | 0 | |
Intangibles to total assets | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | |
Capex to operating cash flow | -0.97 | -0.97 | -0.79 | -1.26 | -0.6 | |
Capex to revenue | -0.05 | -0.09 | -0.11 | -0.1 | -0.06 | |
Capex to depreciation | -1.55 | -3 | -3.7 | -3.1 | -1.82 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 44.33K | 48.68K | 35.63K | 42.97K | 53.73K | |
ROIC | 0.02 | 0.02 | 0 | 0.01 | 0.03 | |
Return on tangible assets | 0.01 | 0.02 | -0.01 | 0.01 | 0.02 | |
Graham Net | -31.87K | -32.71K | -38.83K | -38.06K | -36.71K | |
Working capital | 157.3B | 146.92B | 76.14B | 93.44B | 40.6B | |
Tangible asset value | 489.63B | 501.19B | 475.22B | 517.17B | 541.33B | |
Net current asset value | -190.03B | -198.14B | -273.15B | -251.54B | -250.13B | |
Invested capital | 0.73 | 0.71 | 0.73 | 0.66 | 0.6 | |
Average receivables | 170.82B | 179.63B | 186.77B | 184.97B | 176.44B | |
Average payables | 85.43B | 91.39B | 89.05B | 95.02B | 98.1B | |
Average inventory | 191.69B | 204.84B | 209.57B | 218.87B | 228.06B | |
Days sales outstanding | 50.88 | 48.05 | 53.91 | 48.45 | 46.08 | |
Days payables outstanding | 49.87 | 52.19 | 45.74 | 58.73 | 48.24 | |
Days of inventory on hand | 112.84 | 115.96 | 114.48 | 126.11 | 122.34 | |
Receivables turnover | 1.77 | 1.87 | 1.67 | 1.86 | 1.95 | |
Payables turnover | 1.8 | 1.72 | 1.97 | 1.53 | 1.87 | |
Inventory turnover | 0.8 | 0.78 | 0.79 | 0.71 | 0.74 | |
ROE | 0.03 | 0.03 | -0.02 | 0.02 | 0.04 | |
Capex per share | -1.36K | -2.69K | -3.38K | -2.83K | -1.72K |
069620.KS Frequently Asked Questions
What is Daewoong pharmaceutical Co.,Ltd stock symbol ?
Daewoong pharmaceutical Co.,Ltd is a KR stock and trading under the symbol 069620.KS
What is Daewoong pharmaceutical Co.,Ltd stock quote today ?
Daewoong pharmaceutical Co.,Ltd stock price is $103900 today.
Is Daewoong pharmaceutical Co.,Ltd stock public?
Yes, Daewoong pharmaceutical Co.,Ltd is a publicly traded company.